This company listing is no longer active
Torii Pharmaceutical (4551) Stock Overview
Manufactures and markets pharmaceutical products in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
4551 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Torii Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6,350.00 |
| 52 Week High | JP¥6,470.00 |
| 52 Week Low | JP¥3,540.00 |
| Beta | 0.11 |
| 1 Month Change | 0.47% |
| 3 Month Change | 0.32% |
| 1 Year Change | 70.93% |
| 3 Year Change | 120.79% |
| 5 Year Change | 121.49% |
| Change since IPO | 72.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4551 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 0.3% | 0.3% | -0.2% |
| 1Y | 70.9% | 8.9% | 43.7% |
Return vs Industry: 4551 exceeded the JP Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: 4551 exceeded the JP Market which returned 12.8% over the past year.
Price Volatility
| 4551 volatility | |
|---|---|
| 4551 Average Weekly Movement | 0.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4551 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4551's weekly volatility (0%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1872 | 592 | Nobumasa Kondo | www.torii.co.jp |
Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents for renal diseases and hemodialysis, such as ENAROY tablets to treat anemia associated with CKD; Riona tablets for the treatment of hyperphosphatemia/iron deficiency anemia (IDA); and REMITCH, an oral therapeutic agent for the treatment of pruritus. The company provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; VTAMA cream, a topical treatment for atopic dermatitis and plaque psoriasis; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE.
Torii Pharmaceutical Co., Ltd. Fundamentals Summary
| 4551 fundamental statistics | |
|---|---|
| Market cap | JP¥178.26b |
| Earnings (TTM) | JP¥5.41b |
| Revenue (TTM) | JP¥63.50b |
Is 4551 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4551 income statement (TTM) | |
|---|---|
| Revenue | JP¥63.50b |
| Cost of Revenue | JP¥37.92b |
| Gross Profit | JP¥25.57b |
| Other Expenses | JP¥20.17b |
| Earnings | JP¥5.41b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 30, 2025
| Earnings per share (EPS) | 192.68 |
| Gross Margin | 40.28% |
| Net Profit Margin | 8.52% |
| Debt/Equity Ratio | 0% |
How did 4551 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/02 13:05 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Torii Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. |